This year’s Olympics games grabbed attention beyond the marvellous display of athletic feats. Celebrated gymnast Simone Bile’s decision to pull out of this year’s games to focus on her mental health made headlines across the globe. Her inspirational move proved to be a turning point in destigmatising mental health issues in the athletic world.
Pierluigi Antonelli is CEO at Angelini Pharma.
Following Bile’s example, American sprinter Noah Lyles, women’s pole vault silver medallist Anzhelika Sidorova and Spanish heptathlete Maria Vicente bravely opened up about their own mental health struggles, sparking a long-overdue discussion on a topic too often swept under the carpet.
According to studies, one out of six people in Europe are afflicted with mental health conditions. Mental illnesses are among the top ten most common non-communicable diseases. The devastating socio-economic effects of the COVID-19 outbreak has further triggered a global mental health crisis. Since the pandemic took hold in 2020, the anxiety and stress levels of people across the globe have skyrocketed.
In a recent study, 40 percent of people reported that COVID-19 has had a negative effect on their mental health.
The pandemic has also exacerbated gender-related challenges with its mental health consequences disproportionately affecting women, both at work and at home. According to recent estimates, 83 percent of women report that the pandemic negatively impacted their mental health compared to 36 percent of men.
Pregnant women, women in the postpartum period, or those experiencing trauma such as a miscarriage or abuse from intimate partners, were found to be most susceptible to the psychological impacts of the pandemic.
The burden of household chores and childcare also had a significant impact on women’s mental well-being with 44 percent of women with children under 12 years of age reported they were struggling with household responsibilities as compared to just 20 percent men.
A healthy population is the cornerstone of a thriving and prosperous economy. However, according to the latest estimates, 70 percent of the employed population in Europe suffer from mild to moderate mental health conditions.
Mental illness also has a significant impact on people’s ability to work, limiting their capacity to participate in the labour market. Studies show that employment rates among people with severe mental disorders were as low as 45-55 percent.
The high episodes of absenteeism and presenteeism among people suffering from mental health also results in high costs to the employers’ equivalent to the 1.6 percent of European GDP in loss in labour productivity. The COVID outbreak is further expected to worsen the economic impact of mental health, especially among youth and people from lower socio-economic status.
This further underlines the urgency for addressing the unfurling mental health crisis. With the surge in the number of mental health cases among the workforce, employers have a key role to play in plugging the gaps and responding to the mental health needs of the workforce.
Since its inception fifty years ago, Angelini Pharma has been committed to improving people’s mental health and well-being. Recognising the urgent need for addressing the bubbling mental health crisis in Europe, Angelini Pharma in partnership with The European House Ambrosetti launched Headway in 2017.
A multi-disciplinary platform for knowledge exchange, Headway, aims to prevent, diagnose, and find innovative solutions to reduce the burden of mental health and the associated stigma. The initiative was designed to complement the existing programmes of the World Health Organisation by encouraging strategic reflection and analysis of mental health management across Europe.
It brought together over 40 experts from the medical and scientific community and representatives from patient and family health organisations to spark debate and discussion on best practices for addressing mental health issues.
On October 7, ahead of the world mental health day on October 10, Headway 20233 will be launch